|
| FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer? |
|
https://doi.org/10.18632/oncotarget.27957
Leandro H. Gallo
|
| 1026-1028 |
|
| Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response |
|
https://doi.org/10.18632/oncotarget.27927
Mujib Ullah, Nicole Pek Min Qian, Gustavo Yannarelli
|
| 1029-1031 |
|
| Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting? |
|
https://doi.org/10.18632/oncotarget.27931
Alexander J. Bridges, Ranjit K. Mehta, Sushmita Shukla, Matthew J. Schipper, Theodore S. Lawrence, Mukesh K. Nyati
|
| 1032-1036 |
|
| CEA as a blood-based biomarker in anal cancer |
|
https://doi.org/10.18632/oncotarget.27959
Robert Hester, Shailesh Advani, Asif Rashid, Emma Holliday, Craig Messick, Prajnan Das, Yi-Qian N. You, Cullen Taniguchi, Eugene J. Koay, Brian Bednarski, Miguel Rodriguez-Bigas, John Skibber, Robert Wolff, George J. Chang, Bruce D. Minsky, Wai Chin Foo, Nicole Rothschild, Van K. Morris, Cathy Eng
|
| 1037-1045 |
|
| Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab |
|
https://doi.org/10.18632/oncotarget.27965
Samantha Epistolio, Marco Cefalì, Paolo Spina, Francesca Molinari, Alessandra Movilia, Massimiliano Cergnul, Luca Mazzucchelli, Sara De Dosso, Milo Frattini, Piercarlo Saletti
|
| 1046-1056 |
|
| Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.27964
Chiara Colarusso, Michela Terlizzi, Anne-Sophie Lamort, Ida Cerqua, Fiorentina Roviezzo, Georgios Stathopoulos, Aldo Pinto, Rosalinda Sorrentino
|
| 1057-1071 |
|
| A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation |
|
https://doi.org/10.18632/oncotarget.27962
Esther Baruch, Tali Nizri-Megnaji, Oron Berkowitz, Doron Ginsberg
|
| 1072-1082 |
|
| Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network |
|
https://doi.org/10.18632/oncotarget.27963
Shweta Kishor Sonawane, Subashchandrabose Chinnathambi
|
| 1083-1099 |
|
| Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma |
|
https://doi.org/10.18632/oncotarget.27961
Rami Mäkelä, Ville Härmä, Nibal Badra Fajardo, Greg Wells, Zoi Lygerou, Olle Sangfelt, Juha Kononen, Juha K. Rantala
|
| 1100-1109 |
|
| Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment |
|
https://doi.org/10.18632/oncotarget.27929
Khoa Nguyen, Andrew Rivera, Madlin Alzoubi, Henri Wathieu, Shengli Dong, Hassan Yousefi, Margarite Matossian, Suresh Alahari, David Drewry, Matthew Burow, Bridgette Collins-Burow
|
| 1110-1115 |
|
| Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review |
|
https://doi.org/10.18632/oncotarget.27966
Marco Rubatto, Martina Merli, Gianluca Avallone, Andrea Agostini, Luca Mastorino, Virginia Caliendo, Amelia Barcellini, Viviana Vitolo, Francesca Valvo, Maria Teresa Fierro, Simone Ribero, Pietro Quaglino
|
| 1116-1121 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
